Intel shares fall 1.3% after regulatory delay on $5B Nvidia deal

Traders Union
All News
Financial News
Intel Slips 1.30% Today to $29.19

Highlights

Intel shares trade at $29.19, remaining well above the MA-20 ($25.13), MA-50 ($23.27), and MA-200 ($21.77), confirming a bullish structure across all timeframes.
The dominant catalyst is pending regulatory approval for Intel's $5 billion AI partnership with Nvidia, bolstered by SoftBank funding and an $8.9 billion U.S. government payout, despite ongoing manufacturing challenges.
Momentum indicators are mixed—MACD is bullish, but ADX flashes caution and RSI at 75.06 and CCI at 296.1 signal overbought risks as the stock drops 1.30% intraday.

Investor optimism rises on regulatory deal hopes and governmental funding boost

The pending regulatory approval for the $5 billion strategic AI partnership between INTC and Nvidia is the dominant market driver, as the deal aims to integrate Nvidia's AI stack with INTC's CPUs to advance hybrid computing worldwide. Secondary factors include additional funding from SoftBank and an accelerated $8.9 billion payout from the U.S. government under the Trump administration, both of which have reinforced investor confidence. While these developments have fueled significant market value gains, challenges in core chip manufacturing persist for the company.

Mixed technical signals as intraday loss counters longer-term bullish momentum

Momentum indicators are mixed: the MACD signals sustained upward momentum, but the ADX calls for caution with a sell bias on the daily timeframe. RSI at 75.06 and CCI at 296.1 both signal overbought conditions, while Stoch RSI indicates strong buying. BBP is neutral, showing neither side dominates intraday, and the Awesome Oscillator is neutral, offering no direct trend confirmation. The stock is down 1.30% intraday, having opened with a slight gap up ($29.67 open vs. $29.57 previous close), but has slipped toward the lower end of today's $28.94 – $30.09 range, indicating moderate volatility and clear pressure after the open. Oscillator and momentum signals diverge, with intraday performance matching the loss of momentum highlighted by ADX, despite longer-term bullish trends.

High upside probability as tight trading range supports bullish scenario

For the next five trading days, the expected range is $28.59 – $30.50. The probability of a price increase is very high (more than 80%), with a price decline being less likely. The baseline scenario is continued trading within the $28.59 – $30.50 corridor, as supported by strong weekly and daily moving averages. A bullish scenario could see a breakout above the $30 level, especially if momentum resumes and buyers regain control, while a bearish scenario involves a move below $28.59 and a test of lower support zones.

Viktoras Karapetjanc, Traders Union expert, sees Intel's share structure as overwhelmingly positive, with the recent AI partnership developments and substantial regulatory support reflecting robust investor sentiment and a constructive macro backdrop. He believes that, despite some short-term volatility and lingering operational challenges, institutional funding and ongoing government backing firmly outweigh current doubts. The analyst expects price action to remain strong within the $28.59 – $30.50 corridor, with significant upside potential if momentum recovers. "With such powerful institutional and regulatory tailwinds, I remain confident in INTC’s ability to outperform in the near term as long as bullish momentum holds above key support levels."

Last time we reported that Intel experienced a historic surge after Nvidia announced a major equity investment and strategic partnership. Previously it was noted that massive trading volume followed, as this move comes on the heels of a nearly $9 billion investment from the U.S. government for a 10% Intel stake and SoftBank’s $2 billion position.

Source of Data: INTC Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.